Age (years) | Total pop. | HPV16/18a | Non-16/18 hrHPV only | HPV16/18 only | HPV16/18 and |
---|---|---|---|---|---|
Non-16/18 hrHPV | |||||
% (95 % CI) | % (95 % CI) | % (95 % CI) | % (95 % CI) | ||
30–34 | 7,083 | 2.9 (2.5–3.3) | 10.8 (10.1–11.5) | 1.8 (1.5–2.2) | 1.1 (0.9–1.4) |
35–39 | 7,131 | 2.3 (2.0–2.7) | 9.1 (8.4–9.7) | 1.5 (1.2–1.8) | 0.8 (0.6–1.1) |
40–44 | 6,176 | 1.8 (1.5–2.1) | 7.7 (7.0–8.3) | 1.3 (1.0–1.6) | 0.5 (0.3–0.7) |
45–49 | 4,402 | 1.3 (1.0–1.6) | 7.5 (6.8–8.3) | 0.8 (0.6–1.2) | 0.4 (0.3–0.7) |
50–54 | 2,969 | 1.4 (1.0–1.8) | 8.9 (7.9–10.0) | 0.6 (0.4–1.0) | 0.7 (0.5–1.1) |
55–59 | 2,015 | 1.5 (1.1–2.2) | 9.9 (8.6–11.3) | 0.9 (0.6–1.5) | 0.6 (0.3–1.0) |
60–64 | 1053 | 2.2 (1.5–3.3) | 9.1 (7.5–11.0) | 1.1 (0.7–2.0) | 1.0 (0.6–1.9) |
Total | 30,829 | 2.0 (1.9–2.2) | 9.0 (8.7–9.3) | 1.3 (1.2–1.4) | 0.7 (0.6–0.8) |